SEC Comment Letter for MESOBLAST LTD (MESO, MEOBF) (CIK 0001345099) (MESO) — Jul 19, 2017
MESOBLAST LTD (MESO, MEOBF) (CIK 0001345099)
Date: July 19, 2017 · CIK: 0001345099 · Accession: 0000000000-17-025377
AI Filing Summary & Sentiment
Reasoning
Letter
July 19, 2017 Silviu Itescu Managing Director and Chief Executive Officer Mesoblast Limited 505 Fifth Avenue, Third Floor New York, NY 10017 Mesoblast Limited Registration Statement on Form F-3 Filed July 10, 2017 File No. 333-219210Re: Dear Dr. Itescu: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jeffrey Gabor at (202) 551-2544 with any questions. Division of Corporation Finance Office of Healthcare & Insurance cc: Marc Paul
Show Raw Text
July 19, 2017 Silviu Itescu Managing Director and Chief Executive Officer Mesoblast Limited 505 Fifth Avenue, Third Floor New York, NY 10017 Mesoblast Limited Registration Statement on Form F-3 Filed July 10, 2017 File No. 333-219210Re: Dear Dr. Itescu: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jeffrey Gabor at (202) 551-2544 with any questions. Division of Corporation Finance Office of Healthcare & Insurance cc: Marc Paul